The human ether-à-go-go related gene (hERG) K+ channel (also known as Kv11.1 or KCNH2) is of raising interest in the pharmaceutical industry for drug development because many drugs block it, causing QT interval prolongation, which is a risk factor for ventricular arrythmia and fibrillation that consequently lead to torsades de pointes, a type of polymorphic ventricular tachycardia, and then death. The gene discussed is KCNH2; the disease is polymorphic ventricular tachycardia.